AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Faruqi & Faruqi Investigates Sarepta Securities Class Action.
ByAinvest
Tuesday, Jul 15, 2025 10:36 am ET1min read
Faruqi & Faruqi is investigating Sarepta Therapeutics for potential securities law violations. Investors who purchased Sarepta securities between June 22, 2023 and June 24, 2025 may have legal options. To discuss their options, investors can contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330. The deadline to seek the role of lead plaintiff is August 25, 2025.
NEW YORK, July 2, 2025 — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities law violations by Sarepta Therapeutics, Inc. (NASDAQ: SRPT) on behalf of investors. The firm encourages investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, to contact partner Josh Wilson to discuss their legal options [3].The investigation stems from a class action lawsuit filed against Sarepta, alleging that the company and its executives made false and/or misleading statements and/or failed to disclose significant safety risks associated with ELEVIDYS, a prescription gene therapy for Duchenne muscular dystrophy. The complaint alleges that Sarepta concealed severe side effects, the potential for regulatory scrutiny, and the risk of halting clinical trials and approvals [1][2].
Sarepta's stock price has been significantly impacted by recent adverse events. On March 18, 2025, a patient died following ELEVIDYS treatment, causing the stock to fall by 27.44%. Further disclosures, including the suspension of shipments and dosing in clinical trials, led to additional price declines [3].
Investors who believe they may have suffered losses due to these alleged violations have until August 25, 2025, to request the role of lead plaintiff in the federal securities class action. There is no cost to participate, and any recovery would be distributed among affected investors [1][2].
For more information or to discuss their legal rights, investors can contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330. The firm encourages anyone with information regarding Sarepta's conduct to contact them.
References:
[1] https://www.prnewswire.com/news-releases/sarepta-therapeutics-inc-sued-for-securities-law-violations--investors-should-contact-levi--korsinsky-before-august-25-2025-to-discuss-your-rights--srpt-302502925.html
[2] https://www.morningstar.com/news/pr-newswire/20250711ny28337/sarepta-therapeutics-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-before-august-25-2025-to-discuss-your-rights-srpt
[3] https://www.morningstar.com/news/globe-newswire/9492524/shareholder-reminder-faruqi-faruqi-llp-investigates-claims-on-behalf-of-investors-of-sarepta-therapeutics
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet